Pages

Showing posts with label immunity. Show all posts
Showing posts with label immunity. Show all posts

Saturday, April 10, 2021

Fact check: COVID-19 vaccine not associated with neurodegenerative disease [USAToday, 4 April 2021]

Title:
Fact check: COVID-19 vaccine not associated with neurodegenerative disease
 
Author:
Miriam Fauzia
 
Published:
USAToday (via Yahoo!), 4 April 2021

From the article: 
* The claim: COVID-19 vaccines are associated with prion disease 
 
* With the COVID-19 vaccine rollout advancing at about 2.77 million average doses administered a day – a steady increase since vaccinations began in late December – a supposed research paper is rousing fear about the vaccine's safety on social media.
 
* The source behind Cox's bold claim is a paper titled "COVID-19 RNA Based Vaccines and the Risk of Prion Disease," written by J. Bart Classen.
 
* Contrary to Classen's claim, there is no evidence to suggest the COVID-19 vaccines can cause prion diseases or other neurodegenerative diseases like Alzheimer's.

Tuesday, March 9, 2021

COVID-19 RNA Based Vaccines and the Risk of Prion Disease (by J. Bart Classen) - [Scholarly Article - Microbiology & Infectious Diseases, 2021]

Title:
COVID-19 RNA based vaccines and the riks of prion disease
 
Author:
J. Bart Classen, MD
Classen Immunotherapies, inc, Manchester
 
Published:
Microbiology & Infectious Diseases, 5(1), pp. 1-3 (Received: 27 December 2020; Accepted: 18 January 2021) 

Abstract:
Development of new vaccine technology has been plagued with problems in the past. The current RNA based SARSCoV-2 vaccines were approved in the US using an emergency order without extensive long term safety testing. In this paper the Pfizer COVID-19 vaccine was evaluated for the potential to induce prion-based disease in vaccine recipients. The RNA sequence of the vaccine as well as the spike protein target interaction were analyzed for the potential to convert intracellular RNA binding proteins TAR DNA binding protein (TDP-43) and Fused in Sarcoma (FUS) into their pathologic prion conformations. The results indicate that the vaccine RNA has specific sequences that may induce TDP-43 and FUS to fold into their pathologic prion confirmations. In the current analysis a total of sixteen UG tandem repeats (ΨGΨG) were identified and additional UG (ΨG) rich sequences were identified. Two GGΨA sequences were found. Potential G Quadruplex sequences are possibly present but a more sophisticated computer program is needed to verify these. Furthermore, the spike protein, created by the translation of the vaccine RNA, binds angiotensin converting enzyme 2 (ACE2), a zinc containing enzyme. This interaction has the potential to increase intracellular zinc. Zinc ions have been shown to cause the transformation of TDP-43 to its pathologic prion configuration. The folding of TDP-43 and FUS into their pathologic prion confirmations is known to cause ALS, front temporal lobar degeneration, Alzheimer’s disease and other neurological degenerative diseases. The enclosed finding as well as additional potential risks leads the author to believe that regulatory approval of the RNA based vaccines for SARS-CoV-2 was premature and that the vaccine may cause much more harm than benefit. 

Tuesday, May 5, 2020

Medical Xpress, 5 May 2020 - Recently recovered COVID-19 patients produce varying virus-specific antibodies

Title:
Recently recovered COVID-19 patients produce varying virus-specific antibodies

By:
Cell Press

Published:
Medical Xpress, 5 May 2020

From the article:
"Most newly discharged patients who recently recovered from COVID-19 produce virus-specific antibodies and T cells, suggests a study published on May 3rd in the journal Immunity, but the responses of different patients are not all the same. While the 14 patients examined in the study showed wide-ranging immune responses, results from the 6 of them that were assessed at two weeks after discharge suggest that antibodies were maintained for at least that long."

To read this article:
https://medicalxpress.com/news/2020-05-recovered-covid-patients-varying-virus-specific.html